A phase I study of IRISOX (irinotecan/S-1/oxaliplatin) in the second-line treatment for gemcitabine-refractory pancreatic cancer

被引：0
|
作者：
Miyata, E. [1 ]
Okuwaki, K. [1 ]
Imaizumi, H. [2 ]
Kida, M. [1 ]
Iwai, T. [1 ]
Yamauchi, H. [1 ]
Kaneko, T. [1 ]
Hasegawa, R. [1 ]
Adachi, K. [1 ]
Tadehara, M. [1 ]
Koizumi, W. [1 ]
机构：
[1] Kitasato Univ, Sch Med, Gastroenterol, Sagamihara, Kanagawa, Japan
[2] Sagamino Hosp, Japan Community Hlth Care Org, Gastroenterol, Sagamihara, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
721P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] S-1 monotherapy or in combination with lencovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: A phase II study.
    Ge, Feijiao
    Xu, Nong
    Bai, Yuxian
    Ba, Yi
    Zhang, Yanqiao
    Li, Fei
    Xu, Huayan
    Jia, Ru
    Wang, Yan
    Lin, Li
    Xu, Jian-Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] A case of gemcitabine-refractory pancreatic cancer responsive to second-line chemotherapy using S-1
    Morizane, Chigusa
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (12) : 973 - 973
  • [3] Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients
    Kim, Hyun Jung
    Yun, Jina
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Tae Hoon
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Nam Su
    Moon, Jong Ho
    Park, Sang Heum
    Lee, Kyu Taek
    Park, Seong Kyu
    Won, Jong-Ho
    Park, Hee Sook
    Hong, Dae Sik
    ONCOLOGY LETTERS, 2012, 3 (06) : 1314 - 1318
  • [4] A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.
    Pijnappel, Esther
    de Vos-Geelen, Judith
    Macarulla Mercade, Teresa
    Melisi, Davide
    Pfeiffer, Per
    Prager, Gerald W.
    Van Laarhoven, Hanneke W. M.
    Wilmink, Johanna
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer
    Kawashima, Hiroki
    Itoh, Akihiro
    Ohno, Eizaburo
    Nakamura, Masanao
    Miyahara, Ryoji
    Ohmiya, Naoki
    Hara, Kazuo
    Kanamori, Akira
    Itoh, Terutomo
    Taki, Tomoyuki
    Hirai, Takanori
    Hashimoto, Senju
    Takeda, Kinichi
    Goto, Hidemi
    Hirooka, Yoshiki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (03) : 677 - 683
  • [6] Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer
    Hiroki Kawashima
    Akihiro Itoh
    Eizaburo Ohno
    Masanao Nakamura
    Ryoji Miyahara
    Naoki Ohmiya
    Kazuo Hara
    Akira Kanamori
    Terutomo Itoh
    Tomoyuki Taki
    Takanori Hirai
    Senju Hashimoto
    Kinichi Takeda
    Hidemi Goto
    Yoshiki Hirooka
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 677 - 683
  • [7] An Analysis of a Second-Line S-1 Monotherapy for Gemcitabine-Refractory Biliary Tract Cancer
    Katayose, Yu
    Ohtsuka, Hideo
    Kitamura, Yo
    Masuda, Kunihiro
    Nakagawa, Kei
    Yamamoto, Kuniharu
    Yoshida, Hiroshi
    Onogawa, Tohru
    Motoi, Fuyuhiko
    Naitoh, Takeshi
    Rikiyama, Toshiki
    Egawa, Shin-ichi
    Unno, Michiaki
    HEPATO-GASTROENTEROLOGY, 2012, 59 (115) : 691 - 695
  • [8] Second-Line Therapy for Gemcitabine-Refractory Pancreatic Cancer : Is There a Standard?
    Almhanna, Khaldoun
    Kim, Richard
    ONCOLOGY-NEW YORK, 2008, 22 (10): : 1176 - 1183
  • [9] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Morizane, Chigusa
    Okusaka, Takuji
    Furuse, Junji
    Ishii, Hiroshi
    Ueno, Hideki
    Ikeda, Masafumi
    Nakachi, Kohei
    Najima, Mina
    Ogura, Takashi
    Suzuki, Eiichiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 313 - 319
  • [10] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Chigusa Morizane
    Takuji Okusaka
    Junji Furuse
    Hiroshi Ishii
    Hideki Ueno
    Masafumi Ikeda
    Kohei Nakachi
    Mina Najima
    Takashi Ogura
    Eiichiro Suzuki
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 313 - 319
12345